RxDoctor Payments Data

Wayne Lucas, MD

Gastroenterology · Pinehurst, NCNPI 1932141223

Payments from drug & device makers

$5,788in general payments, 2019–2025

Across 187 payments — averaging $30.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$394
  • Steris Corporation$358
  • Gilead$337
  • Takeda Pharmaceuticals U.S.A., Inc.$293
  • Pfizer$196
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,75099%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,788 in reported general payments places this provider in the 65th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$484,882
Medicare patients
738
Services billed
33,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab37$421,279
StelaraUstekinumab11$291,418
PentasaMesalamine12$23,039
LinzessLinaclotide17$11,877
Rabeprazole Sodium259$8,646
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg257$6,164
Dexlansoprazole DrDexlansoprazole21$5,041
Omeprazole436$4,814
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates37$2,697
Sucralfate19$2,406
Lubiprostone19$2,362
Colestipol Hcl51$2,173
Ursodiol15$2,100
Esomeprazole Magnesium49$1,607
Azathioprine37$1,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$394$291,41811 claims
AbbVieLinzess$2,274$11,87717 claims
SandozLansoprazole$21$49924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →